Clexio Biosciences Ltd.

ACTIVE

Israelwww.clexio.comPrivate11–50 employeesEstablished: 2018-03-01

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2018

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

75.0%

Phase 1

25.0%

Trial Status Distribution

Completed

75.0%

Recruiting

25.0%

Clinical Trials

Trials sponsored by this organization (4)

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

Phase 2

Completed

interventional

Mar 202499 participants

A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica

Phase 2

Completed

interventional

Jan 202459 participants

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

Phase 2

Completed

interventional

Sep 2019146 participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CLE-905-AG, a M1/M4 Muscarinic Agonist when administered alone or in conjunction with a Peripheral Muscarinic antagonist, in Healthy Participants

Phase 1

Recruiting

110 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations